For nearly twenty years, a woman in China had not seen her own child's face. She lost her sight as a teenager to retinitis pigmentosa and lived in total darkness. This spring, a small chip placed in her eye let her look at a page and write, by hand, the two characters for "China" (中国).
It was not a cure. The light did not return to her eye. Instead, a machine rebuilt a new path for vision where the old one had collapsed.
Key takeaways
- The device is a retinal-pathway visual brain-computer interface (脑机接口) made by Hangzhou Nuanced Chip (暖芯迦电子科技), founded in 2014 by Yang Jiawei (杨佳威) after he returned from the University of Melbourne's neuroengineering center.
- A first-in-China clinical implant of the 320-channel version was performed in May 2026 at Zhejiang Provincial People's Hospital (浙江省人民医院); a second site, the Hangzhou branch of the Eye and ENT Hospital affiliated with Wenzhou Medical University, opened its trial in June 2026.
- The implanted chip is about 3 mm by 3 mm and 0.5 mm thick, carrying 320 stimulation channels placed in the macula; surgery took roughly five hours and the patient went home the next day.
- About two months after activation, the patient could write characters, grab a computer mouse and a bottle, and walk independently along a line and around a corner.
- The team plans about 30 human implants in 2026 and is developing a next-generation 1,280-channel chip.
How a blind eye learns to "see" again
The patient's retina no longer worked, but the rest of the pathway — the optic nerve and the visual cortex — was intact. The system works around the dead tissue. A custom pair of glasses carries a tiny camera that captures the scene; an external processor turns the image into a neural code; that code is sent wirelessly to the chip inside the eye, which uses 320 electrodes to stimulate the surviving retinal ganglion cells. Those cells then carry the signal up the optic nerve to the brain, which assembles an image.
As the company's vice president put it, the goal is not to restore natural sight but to rebuild vision: the camera stands in for the eye, the chip for the broken retina. The patient currently sees in black and white with about 256 shades of gray — enough to read contours and spatial layout, with functional vision described as roughly 0.1 on the eye chart and up to 0.1-equivalent detail with camera magnification.
From a blind monkey to a writing hand
The human result follows an animal milestone. In 2025, Nuanced Chip reported that a fully blind macaque, after receiving a high-resolution visual implant, could locate and grab a small ball — the proof point that the concept could cross from simulation to a living visual system. The leap to a person who writes characters took under a year.
Writing Chinese characters is a deliberately hard test. It demands far more visual resolution than recognizing a letter: the patient must discern stroke order and structure, keep the pen tip in view, and convert what she sees into hand movement. That she could do it suggests the restored signal is being reorganized by the brain into something usable, not just flashes of light.
Scale, cost and the next chip
Nuanced Chip says it spent close to ¥100 million (about US$14 million / HK$109 million) building a 90-step GMP clean production line from scratch, because no domestic supplier existed for the micron-scale parts and biocompatible materials. The company has also started a U.S. FDA filing, aiming to take the "made in China" approach global.
On cost, the founder has said a domestic device might land in the ¥100,000–150,000 range (about US$14,000–21,000 / HK$109,000–164,000), versus an overseas comparable priced at US$200,000–250,000. That comparison is the company's own estimate and should be read as a target, not a list price. A 1,280-channel next-generation chip is in development for patients whose eyeball was removed or whose optic nerve is fully severed, where a cortical-pathway device would be needed instead.
Honest limitations
This is still early, small-scale clinical work, not approved standard care. The public record we found covers roughly one detailed patient case plus a stated plan for about 30 implants in 2026 — far too few to speak about safety across a population. The restored vision is low-resolution and monochrome, useful for orientation rather than reading a book. The cost figures are the founder's statements, not published prices, and a U.S. FDA filing is a beginning, not an approval. We did not independently verify the 90-step line's capacity or any long-term implant durability beyond the reported animal data.
What readers can do now
- Families of retinitis pigmentosa or macular-degeneration patients should ask treating hospitals whether a visual-BCI trial is open and under which institution's ethics approval — and treat any "available now" offer with caution.
- Follow two distinct numbers as the real progress markers: the count of implanted patients (the team targets ~30 in 2026) and the channel count of the next chip (1,280), which determines how much finer the restored vision can get.
- If you are outside China, watch the FDA filing status of Nuanced Chip as the first sign this approach could reach non-Chinese patients.